Company Filing History:
Years Active: 2015-2016
Title: Michael John Bromley: Innovator in Antifungal Research
Introduction
Michael John Bromley is a notable inventor based in Halifax, GB. He has made significant contributions to the field of antifungal research, holding two patents that focus on innovative methods for identifying antifungal agents. His work is crucial in the ongoing battle against fungal infections, which pose serious health risks.
Latest Patents
Bromley's latest patents include a method for identifying an antifungal agent that targets a PPTB protein of a fungus. This method involves determining whether a candidate compound binds to or inhibits the PPTB protein, with binding or inhibition indicating that the candidate substance is an antifungal agent. Another significant patent focuses on dihydroorotate dehydrogenase (DHODH) as an antifungal drug target. This method also involves contacting a candidate substance with a fungal DHODH protein and determining whether the candidate substance binds or modulates the DHODH protein, indicating its potential as an antifungal agent. Specific examples in this patent concern DHODH proteins, and it also discloses DHODH inhibitors with a quinazolinone core.
Career Highlights
Bromley is currently associated with F2G Limited, a company dedicated to developing novel antifungal therapies. His work at F2G Limited has positioned him as a key player in the field of antifungal drug development. His innovative approaches and research have the potential to lead to significant advancements in treating fungal infections.
Collaborations
Bromley collaborates with notable colleagues, including Jason David Oliver and John Leslie Thain. Their combined expertise enhances the research and development efforts at F2G Limited, fostering an environment of innovation and discovery.
Conclusion
Michael John Bromley is a distinguished inventor whose work in antifungal research is paving the way for new treatments. His patents reflect a commitment to addressing critical health challenges posed by fungal infections. Through his career at F2G Limited and collaborations with esteemed colleagues, Bromley continues to make impactful contributions to the field.